Associate toxin-antitoxin with CRISPR-Cas to kill multidrug-resistant pathogens.
Rui WangXian ShuHuiwei ZhaoQiong XueChao LiuAici WuFeiyue ChengLingyun WangYihan ZhangJie FengNannan WuMing LiPublished in: Nature communications (2023)
CreTA, CRISPR-regulated toxin-antitoxin (TA), safeguards CRISPR-Cas immune systems by inducing cell dormancy/death upon their inactivation. Here, we characterize a bacterial CreTA associating with the I-F CRISPR-Cas in Acinetobacter. CreT is a distinct bactericidal small RNA likely targeting several essential RNA molecules that are required to initiate protein synthesis. CreA guides the CRISPR effector to transcriptionally repress CreT. We further demonstrate a proof-of-concept antimicrobial strategy named ATTACK, which AssociaTes TA and CRISPR-Cas to Kill multidrug resistant (MDR) pathogens. In this design, CRISPR-Cas is programed to target antibiotic resistance gene(s) to selectively kill MDR pathogens or cure their resistance, and when CRISPR-Cas is inactivated or suppressed by unwanted genetic or non-genetic events/factors, CreTA triggers cell death as the last resort. Our data highlight the diversity of RNA toxins coevolving with CRISPR-Cas, and illuminate a combined strategy of CRISPR and TA antimicrobials to 'ATTACK' MDR pathogens.
Keyphrases
- crispr cas
- genome editing
- multidrug resistant
- gram negative
- acinetobacter baumannii
- drug resistant
- cell death
- genome wide
- escherichia coli
- klebsiella pneumoniae
- copy number
- electronic health record
- single cell
- bone marrow
- pseudomonas aeruginosa
- dendritic cells
- stem cells
- gene expression
- cell therapy
- big data
- immune response
- artificial intelligence
- cancer therapy
- cell cycle arrest